



- (51) **International Patent Classification:**
A61K 31/513 (2006.01) *A61P 9/04* (2006.01)
- (21) **International Application Number:**
PCT/US2023/019710
- (22) **International Filing Date:**
25 April 2023 (25.04.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/335,028 26 April 2022 (26.04.2022) US
63/335,209 26 April 2022 (26.04.2022) US
63/336,254 28 April 2022 (28.04.2022) US
- (71) **Applicant:** MYOKARDIA, INC. [US/US]; 1000 Sierra Point Parkway, Brisbane, California 94005 (US).
- (72) **Inventors:** PERERA, Vidya V.; Lawrenceville, New Jersey (US). MERALI, Samira; Lawrenceville, New Jersey (US). SEHNERT, Amy; Brisbane, California (US). CHEUNG, Michael; Brisbane, California (US). SETO, Dewey; Summit, New Jersey (US). LOCKMAN, Jeffrey; Lawrenceville, New Jersey (US). PAPI, Marie-Laure; Lawrenceville, New Jersey (US).
- (74) **Agent:** CHIPOURAS, Andrew S.; Honigman Llp, 650 Trade Centre Way, Suite 200, Kalamazoo, Michigan 49002-0402 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,


(54) **Title:** METHODS OF ADMINISTERING MYOSIN INHIBITORS

FIG. 1

(57) **Abstract:** Methods of administering a myosin inhibitor to a patient and related methods of risk mitigation including controls on distribution are described herein. Methods disclosed herein provide for safe administration of mavacamten and other myosin inhibitors, and mitigate the risk of heart failure due to systolic dysfunction.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*